e-learning
resources
ERJ
2009
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results
Crim C., Calverley P. M. A.,,erson J. A., Celli B., Ferguson G. T., Jenkins C., Jones P. W., Willits L. R., Yates J. C., Vestbo J.
Source:
Eur Respir J 2009; 34: 641
Journal Issue:
September
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Crim C., Calverley P. M. A.,,erson J. A., Celli B., Ferguson G. T., Jenkins C., Jones P. W., Willits L. R., Yates J. C., Vestbo J.. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009; 34: 641
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Inhaled corticosteroids and the risk of a first exacerbation in COPD patients
Source: Eur Respir J 2004; 23: 692-697
Year: 2004
The role of nebulised budesonide in the treatment of exacerbations of COPD
Source: Eur Respir J 2007; 29: 660-667
Year: 2007
Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia
Source: Eur Respir J 2010; 36: 751-757
Year: 2010
Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia
Source: Eur Respir J 2011; 37: 36-41
Year: 2011
Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids
Source: Annual Congress 2006 - COPD therapy
Year: 2006
Inhaled corticosteroids and hospitalisation due to exacerbation of COPD
Source: Eur Respir J 2003; 22: 286-289
Year: 2003
Risk of pneumonia and exacerbations of chronic obstructive pulmonary disease(COPD) with inhaled corticosteroid (ICS) use: a Singapore perspective
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018
A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD
Source: Annual Congress 2013 –Risk factors for COPD and lung function decline
Year: 2013
Medication use in COPD: systematic review and meta-analysis
Source: Annual Congress 2007 - Treatment and care of COPD
Year: 2007
The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Inhaled maintenance therapy and risk of first or subsequent emergency department visit/hospitalization in patients with COPD
Source: Annual Congress 2006 - COPD therapy
Year: 2006
Low-dose inhaled and nasal corticosteroid use and the risk of cataracts
Source: Eur Respir J 2006; 27: 1168-1174
Year: 2006
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment
Source: Eur Respir J 2006; 27: 964-971
Year: 2006
The efficacy and safety of inhaled fluimucil-antibiotic-IT in the treatment of exacerbations of COPD and chronic bronchitis with bronchiectasis
Source: Annual Congress 2013 –COPD diagnosis
Year: 2013
Safety of salmeterol / fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year
Source: Eur Respir J 2002; 20: Suppl. 38, 242s
Year: 2002
The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter?
Source: Eur Respir J 2003; 21: 260-266
Year: 2003
Comparing pneumonia incidence in COPD patients treated with or without inhaled corticosteroid
Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data
Year: 2021
Withdrawal of inhaled corticosteroids in people with chronic obstructive pulmonary disease (COPD) in primary care – a randomised controlled trial
Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD
Year: 2005
Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol
Source: Eur Respir J 2004; 24: Suppl. 48, 291s
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept